In re Novartis and Par Antitrust Litigation

  1. July 26, 2023

    Novartis Direct Buyers' Attys Get $42M In Drug Delay Case

    A New York federal judge awarded counsel for direct purchasers of Novartis' hypertension medication $42.15 million in attorney fees, according to an order Tuesday granting final approval of a $126 million settlement resolving claims that Novartis had an illicit arrangement with Par Pharmaceuticals to delay the release of an Exforge generic.

  2. February 23, 2023

    End-Payors Ink $30M Novartis Exforge Deal

    Novartis has reached another deal to shake off claims that it hatched an illegal deal with Par Pharmaceuticals to delay the release of a generic version of the blood pressure drug Exforge, this one with end payors for $30 million.

  3. February 22, 2023

    End Payors Latest To Drop Bankruptcy-Blocked Par Claims

    Health benefit funds and other end payors became the latest plaintiffs Wednesday to drop Par Pharmaceuticals, now in the middle of bankruptcy, from consolidated litigation accusing the drugmaker and Novartis of hatching an illegal deal to delay generic versions of the blood pressure drug Exforge.

  4. January 09, 2023

    Novartis Gets OK On $126M Deal To End Drug Delay Claims

    Novartis will pay $126 million to end claims brought by a group of direct purchasers accusing the pharmaceutical giant of hatching an illegal deal with Par Pharmaceuticals to delay the release of a generic version of the blood pressure drug Exforge.

  5. January 03, 2023

    Health & Pharma Legal Clashes Didn't Take A Holiday Break

    While many Americans were bringing glad tidings and popping bubbly, attorneys spent the final week of 2022 bringing lawsuits, appeals and other court filings of eye-popping significance for health care providers and drug companies in cases involving the False Claims Act, the opioid crisis and purported price-fixing schemes.

  6. November 08, 2018

    Exforge Deal 'More Pernicious' Than Actavis, Court Told

    An alleged deal between Novartis and Par Pharmaceutical to delay a generic of hypertension medication Exforge is illegal because it was far more anticompetitive than what the U.S. Supreme Court dealt with in its landmark Actavis decision, Walgreens and Kroger told a New York federal court Wednesday.

  7. October 25, 2018

    Exforge Generic Deal Is Clear Antitrust Violation, Court Told

    A proposed class of drug buyers told a New York federal court Wednesday that an agreement between Novartis Pharmaceuticals Corp. and Par Pharmaceutical Inc. that allegedly delayed the launch of a generic version of hypertension medication Exforge is illegal on its face and doesn't need a closer look.

  8. May 16, 2018

    Novartis, Par Hit With Pay-For-Delay Suit Over Exforge

    Novartis Pharmaceuticals Corp. was able to keep a generic of its hypertension drug Exforge off the market for years by agreeing to let Par Pharmaceutical Inc. have six months of generic exclusivity, a deal that shunned competition and kept prices higher, according to a proposed class action filed in New York federal court Wednesday.